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The therapeutic promise of the organic nitrates remains in-
triguingly unfulfilled after a century of clinical experience. Two
recent studies provide a glimpse of potential efficacy, both in
the management of congestive heart failure and of evolving
myocardial infarction (1,2). For example, Cotter et al. (1)
demonstrated that intravenously infused isosorbide dinitrate
(ISDN) improves symptomatic status in patients with acute
pulmonary edema, possibly via reduced risk of development of
acute myocardial infarction. Furthermore, in the ISIS-4 trial
(Fourth International Study of Infarct Survival) (2), oral
isosorbide mononitrate (ISMN) therapy was associated with
approximately a 20% reduction in mortality during the first
24 h after acute myocardial infarction.
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On the other hand, numerous studies attest to the
observation that the various actions of organic nitrates,
whether vasodilator or anti-aggregatory, tend to diminish
during long-term nitrate therapy, and this phenomenon,
loosely termed nitrate tolerance, is associated with progres-
sive attenuation of the therapeutic effects of nitrates, irre-
spective of whether the end point measured is hemodynamic
(in congestive heart failure), anti-ischemic (in angina pec-
toris) or associated with post-infarct outcome.
Considerable progress has been made on the basis of
recent studies delineating the major factors restricting effi-
cacy of organic nitrate therapy. These may be categorized as:
1) nitrate resistance: de novo impairment of tissue respon-
siveness to organic nitrates and to nitric oxide, 2) “true”
nitrate tolerance: progressive desensitization of blood vessels
and/or platelets to biological effects of organic nitrates, and
3) “pseudo-tolerance”: algebraic attenuation of the effects of
organic nitrates in vitro through increased secretion of
substances exerting biologically opposing effects.
There is general agreement that “nitrate resistance” shares
pathogenetic mechanisms with endothelial dysfunction, and is
manifest both in vasculature (3) and in platelets (4). Increased
secretion of catecholamines, angiotensin II and endothelin
have been demonstrated in various models (5,6): irrespective of
mechanism(s), it is generally agreed that pseudo-tolerance
underlies the phenomenon of “rebound” ischemia after sudden
cessation of nitrate therapy (7). On the other hand, the
mechanism(s) underlying the development of “true” nitrate
tolerance remain controversial, with no-clear cut strategies
available for circumvention of this problem.
As recently summarized in a number of reviews (8–10),
two major categories of mechanism have been proposed for
the development of “true” nitrate tolerance: impaired enzy-
matic release of nitric oxide (NO) from organic nitrates
(“impaired bioconversion”) and increased endothelial gen-
eration of superoxide, impairing both responses to organic
nitrates and to agents stimulating release of NO from
vascular endothelium. While it has recently been proposed
that these two categories may be linked (10), little evidence
of a single over-arching mechanism is currently available.
Part of the problem associated with evaluation of mecha-
nism of nitrate tolerance lies in the choice of available meth-
odology. While clinical studies (e.g., measuring exercise per-
formance) may document attenuation of therapeutic effect, it is
difficult to delineate the relative role(s) of “true” versus pseudo-
tolerance in this attenuation. Furthermore, the choice of
subjects may be critical: e.g., studies in normal subjects may be
used to demonstrate progressive impairment of endothelial
function during chronic nitrate therapy, but the relevance of
this change is probably exaggerated relative to that potentially
occurring patients in whom endothelial dysfunction is likely to
be present at the time of initiation of nitrate therapy.
Major evidence in favor of the “impaired bioconversion”
hypothesis includes the fact that nitrate tolerance can be
induced in vitro, under which circumstances it is largely,
although not entirely, specific for organic nitrates, with
minimal cross-tolerance to direct NO donors or authentic
NO (11,12). Furthermore, under a number of circumstances
in both human and animal models, induction of nitrate
tolerance is associated with little if any change in measures
of oxidative stress and/or endothelial function (13–16).
Furthermore, induction of tolerance by glyceryl trinitrate
(GTN) in patients with stable angina pectoris was associ-
ated with impairment of biotransformation of GTN to
glyceryl 1,2-dinitrate (1,2-GDN) (15). Finally, Chen et al.
(17) have recently identified aldehyde dehydrogenase as
the major enzyme system catalysing nitrate bioconversion
to 1,2-GDN in rabbit aortae and mouse macrophage cells.
Purified aldehyde dehydrogenase, which has an active site
thiol group, catalyzes 1,2-GDN formation only in the
presence of additional thiols, consistent with previous
findings that the effects of GTN in stimulating activation
of soluble guanylate cyclase were sulfhydryl-dependent
in vitro (18), and that certain sulfhydryl agents, such as
N-acetylcysteine (NAC) potentiate the hemodynamic and
anti-aggregatory effects of organic nitrates (19,20). It was
therefore postulated by Chen et al. (17) that nitrate toler-
ance reflected progressive inhibition of aldehyde dehydro-
genase activity. Indeed, GTN and isosorbide dinitrate have
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been reported to inhibit aldehyde dehydrogenase both in
vitro and in vivo (21).
There is also considerable evidence that nitrate tolerance is
sometimes associated with incremental impairment of endo-
thelial function, largely due to generation of superoxide (O2
)
free radical. While it is true that some NO donors, such as
GTN, generate O2
 during enzymatic bioconversion (22), the
majority of studies suggest that chronic continuous in vivo
exposure to high doses of GTN both in animal models and in
humans, sometimes induces incremental O2
 generation and
resultant evidence of redox stress (23–25). While the endothe-
lium represents the principal source of O2
, both the
NAD(P)H oxidase system (23) and dysfunctional endothelial
nitric oxide synthase (eNOS)(24) appear to contribute to O2

generation. Both of these findings are of potential therapeutic
importance as NAD(P)H oxidase expression is stimulated by
angiotensin II while “uncoupling” of eNOS (to generate O2

rather than NO) may occur in the absence of its cofactor
tetrahydrobiopterin (BH4) (26) or with depletion of arginine
levels. On the other hand, eNOS knockout mice do not display
altered susceptibility to induction of GTN tolerance (27).
Irrespective of precise mechanism, the implication of a central
role of O2
 generation in nitrate tolerance would be attenua-
tion of endogenous endothelium-dependent NO physiological
effects, whether vasodilator or anti-aggregatory. This cross-
tolerance to endogenous NO, which has been documented in
many animal models of GTN-induced tolerance and in some
human studies, would imply that nitrate therapy might be
potentially harmful to long-term clinical outcomes.
In the this issue of the Journal, Mu¨ller et al. (28) reported the
characteristics of nitrate tolerance induced in rabbits via 4
months eccentric dosing with high doses (200 mg/kg/day) of
ISMN. Tolerance was assessed by examination of reactivity of
aortic rings in comparison with those of control animals. The
main findings were that in the presence of a moderate level of
tolerance to ISMN (approximately a five-fold increase in
ISMN dose to produce 50% relaxation responses) there was
neither cross-tolerance to the direct NO donor S-nitroso-N-
acetyl penicillamine, nor any diminution of relaxations to the
endothelial-dependent vasodilator acetylcholine. Furthermore,
superoxide production was unchanged in vessels from tolerant
animals. Hence it can be concluded that in this model of
nitrate tolerance induced by long term ISMN administration
there is neither induction of endothelial dysfunction nor
cross-tolerance to NO. Although not specifically assessed, the
findings are consistent with impairment of nitrate bioconver-
sion as a mechanism for tolerance induction.
What are the implications of these findings? First, this
provides incremental evidence that tolerance induction in
vivo may be relatively nitrate-specific, that is, similar to in
vitro tolerance, under some circumstances; this finding is
consistent with some, but not all, previous findings in man.
It also follows that the induction or aggravation of endo-
thelial dysfunction is a variable, rather than constant,
component of nitrate-tolerant states. Nevertheless, some
important issues remain unanswered. For example, aortic
smooth muscle may not be fully representative of regional
vasomotor sites for organic nitrates: in a recent human
study, one to two days of continuous high-dose intravenous
GTN infusion induced nitrate-specific tolerance in saphe-
nous veins, but there was impairment of endothelial func-
tion in internal mammary and radial arteries (29). Second, it
is not clear to what extent the findings depend on the nitrate
inducing tolerance and/or the nitrate examined in the
tolerant setting. Based upon previous in vitro results (11,12),
it is possible that the small shift in the ISDN concentration-
response curve in the study by Mu¨ller et al. (28) may have
corresponded with far greater inhibition of GTN responses;
however this was not specifically examined. Furthermore,
the majority of in vivo studies in which tolerance induction
was associated with increased oxidative stress have utilized
GTN as a tolerance-inducing agent, and it certainly remains
possible that continuous high-dose GTN therapy induces a
different form of tolerance, as well as a greater degree of
tolerance, compared to some other nitrates.
An understanding of the mechanism(s) underlying nitrate
tolerance induction must be a precursor to clinical studies
evaluating possible means of circumvention of tolerance; these
studies should also extend to evaluating the efficacy of
tolerance-modifying regimes in the clinical setting. To date, a
number of agents have been evaluated clinically as regards
interactions with nitrate tolerance induction. Data are limited
and inconsistent (Table 1). In particular, utilization of
angiotensin-converting enzyme (ACE) inhibitors (and ATI
antagonists) has not been associated with marked amelioration
of nitrate efficacy, despite the known effects of ACE inhibitors
in reversing endothelial dysfunction. Folic acid, which clearly
improves endothelial dysfunction in many settings (30), also
Table 1. Agents Postulated to Limit or Reverse Development of Nitrate Tolerance
Agent
Evidence of
Clinical Efficacy* Potential Mechanism(s) of Action
ACE inhibitors Inconsistent Prevention of NAD(P)H oxidase activation
Hydralazine ?VHeFT Inhibition of NAD(P)H oxidase
Ascorbic acid    Limitation of oxidative stress
Folic acid    Re-coupling of NO synthase
L-arginine Limited Increased NO generation
N-acetylcysteine Unstable angina ?Potentiation of nitrate bioconversion
Acute pulmonary edema Limitation of oxidative stress
*Based upon improvement of exercise tolerance and/or outcomes.
ACE angiotensin-converting enzyme; NAD(P)H reduced nicotinamide adenine dinucleotide (phosphate); NO nitric
oxide.
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potentiates hemodynamic responses to GTN (31). However, it
is not clear that this potentiation involves a specific interaction
with the process of tolerance induction, and the therapeutic
implications remain untested. N-acetylcysteine potentiates the
vasodilator and anti-aggregatory effects of GTN in many
settings, and appears useful in combination with GTN in
unstable angina (32) as well as in acute pulmonary edema and
possibly acute myocardial infarction. However, NAC both po-
tentiates GTN-induced activation of soluble guanylate cyclase
(33) (suggesting an effect on bioconversion) and also exerts
well-documented anti-oxidant effects. It remains controversial
to what extent the clinical efficacy of NAC reflects a specific
interaction with nitrate tolerance.
In summary, we can conclude that nitrate tolerance
induction involves a nitrate-specific (bioconversion?) com-
ponent in most cases, with a variable component of in-
creased oxidative stress and incremental endothelial dys-
function. It can be anticipated that the biological role of
aldehyde dehydrogenase in catalyzing NO release from
organic nitrates in humans will soon be more completely
understood. With this will emerge a biochemical means for
“on-line” evaluation of the efficacy of nitrates during chronic
therapy, which in turn should facilitate clinical efficacy
studies. This progress has been a long time coming.
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